• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Recent researches in modern medicine >Varenicline as first aid to treat nicotine dependence in smokers with high prevalence of co-morbidities
【24h】

Varenicline as first aid to treat nicotine dependence in smokers with high prevalence of co-morbidities

机译：瓦伦尼克林是治疗合并症高发烟民的尼古丁依赖的急救药物

获取原文
获取原文并翻译 | 示例
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Varenicline is a first line smoking cessation pharmacotherapy. Smokers with comorbidities are prevalent in our center. The aim of the study was to assess efficacy and safety of varenicline in current practice of a smoking cessation center treating smokers with high prevalence of concomitant disorders. 98 smokers with concurrent stable respiratory, cardiovascular, digestive and psychiatric disorders (study group) and 116 healthy smokers (control group) were treated with varenicline in a 12 weeks cure to quit smoking. Primary end point was carbon monoxide confirmed continuous abstinence rate in the study group at weeks 9-12. Secondly, varenicline safety, discontinuation profile and compliance to treatment were monitored. 41.8% smokers with comorbidities (25/52cardiovascular, 9/26 respiratory, 4/13 digestive, 3/7 psychiatric) and 40.5% healthy smokers successfully quit smoking. Withdrawal symptoms and adverse effects picture did not differ significantly between groups. Varenicline is an effective and highly compliant therapy for smoking cessation in smokers with comorbidities. Safety profile of varenicline is comparable in healthy smokers and smokers with stable comorbidities.
机译：瓦伦尼克林是戒烟的一线药物治疗。有合并症的吸烟者在我们中心很普遍。这项研究的目的是评估伐尼克兰在戒烟中心目前治疗高发病率并发吸烟者中的有效性和安全性。 98例同时出现稳定的呼吸，心血管，消化和精神疾病的吸烟者（研究组）和116例健康的吸烟者（对照组）接受了伐尼克兰治疗，戒烟时间为12周。主要终点是研究组在9-12周时确认的一氧化碳持续戒断率。其次，监测了伐尼克兰的安全性，停药情况和对治疗的依从性。 41.8％的合并症患者（心血管疾病为25/52，呼吸系统9/26，消化系统4/13，精神病患者3/7）和40.5％的健康吸烟者成功戒烟。两组之间的戒断症状和不良反应图像无显着差异。 Varenicline是一种有效且高度顺从的疗法，用于合并症的吸烟者戒烟。伐尼克兰的安全性在健康吸烟者和合并症稳定的吸烟者中具有可比性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号